DF-006 is a first-in-class, orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver 1. DF-006 has successfully completed single and multiple ...

Immunity to hepatitis B virus (HBV) induced through vaccination may offer protection against diabetes. In a study, researchers found that individuals with no prior HBV infection but with measurable ...

Switching to a long-acting cabotegravir/rilpivirine antiretroviral regimen may be safe for patients with HIV who have prior hepatitis B virus exposure, a real-world study shows.

Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has completed financing totaling $56 ...

The innate immune system in mammals defends against infection from viruses and other microbial infections. Unfortunately, the human immune response to the hepatitis B virus (HBV) is not yet fully ...

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) and published in the journal Diagnostics shows that ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced that the chronic ...